Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.58 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | IL6 | P05231 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898758 | 0.95 | TLR7 (0.59) | TLR7IL6TLR8 | |
| SCHEMBL4591271 | 0.95 | TLR7 (0.51) | TLR7NUDT1IL6TLR8DRD2 | |
| SCHEMBL4576892 | 0.89 | TLR7 (0.51) | TLR7IL6TLR8 | |
| SCHEMBL4576572 | 0.88 | TLR7 (0.63) | TLR7NUDT1TLR8 | |
| SCHEMBL4578268 | 0.87 | TLR7 (0.59) | TLR7NUDT1TLR8 | |
| SCHEMBL4576857 | 0.86 | TLR7 (0.44) | TLR7DRD2DRD4DRD3 | |
| SCHEMBL4576840 | 0.84 | TLR7 (0.58) | TLR7NUDT1TLR8 | |
| SCHEMBL4577261 | 0.83 | TLR7 (0.64) | TLR7TLR8 | |
| SCHEMBL4576568 | 0.83 | TLR7 (0.58) | TLR7NUDT1 | |
| SCHEMBL4576929 | 0.83 | TLR7 (0.55) | TLR7NUDT1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | claimed |
| EP-1939199-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | claimed |
| US-20080269240-A1 | Novel Adenine Compound | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1939199-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269240-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | TLR7 612/4885NUDT1 7/4885IL6 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.